RAF1 and malignant colon neoplasm: In another study, Kubiniok and colleagues studied the cancer cell responses to RAF inhibitors, and compared temporal changes in the phosphoproteome of two colon cancer cell lines that respond differently to vemurafenib (an RAF inhibitor), Colo205 and HCT116.